SecBot SecBot
8-K ·Filed May 14, 2026

FBRX

Forte Biosciences, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-224214
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The $172.5M April equity raise extends cash runway into 2027, de-risking upcoming Phase 2 celiac and Phase 1b vitiligo/alopecia readouts. Fast Track designation adds regulatory momentum. However, the EPS miss and accelerating burn rate cap upside. Monitor topline data catalysts, celiac Phase 2 results are the primary swing factor for the stock.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.11
T+0 close · May 14, 2026 · via day close
Latest settled
+232.63%
T+60 · $76.87
Vs SPY
+228.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $23.11entry
  2. T+1 · 6mo ago −9.26%α −9.20% · $20.97
  3. T+5 · 6mo ago −6.58%α −7.54% · $21.59
  4. T+20 · 5mo ago −21.90%α −24.01% · $18.05
  5. T+60 · 3mo ago +232.63%α +228.11% · $76.87

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences reported Q1 2026 net loss of $1.24/share, wider than the $0.98 consensus miss, with no revenue. The key positive is FB102 receiving FDA Fast Track Designation for celiac disease, but the net loss deepened to $22.1M from $15.7M a year ago. A $172.5M April offering (6.6M shares) provides cash runway through upcoming Phase 2 celiac and Phase 1b vitiligo/alopecia readouts.

Key Financial Metrics

EPS
−$1.24
est −$0.98 · -26.5%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q1 2026 net loss per share $(1.24) vs consensus $(0.98), a 26.5% miss
  • Net loss widened to $22.1M from $15.7M in Q1 2025, driven by R&D spend up 62% to $20.5M
  • FB102 received FDA Fast Track Designation for celiac disease
  • Cash and equivalents $58.2M at March 31, 2026, supplemented by $172.5M gross April offering (6.6M shares)
  • Phase 2 celiac topline data expected in 2026; Phase 1b vitiligo data expected shortly; alopecia areata data in 2026
  • Weighted average diluted shares rose 56% YoY to 17.8M, reflecting prior equity raises

Financial Impact

Net loss per share $(1.24) vs consensus $(0.98); R&D spend $20.5M (+62% YoY); cash burn rate ~$22M/quarter pre-April offering

epsnet losscashdilution

Risk Factors

  • Clinical trial failure, Phase 2 celiac data may not replicate Phase 1b positive results
  • Dilution, 6.6M new shares from April offering plus 4.0M prefunded warrants overhang
  • Cash burn, operating expenses running ~$22M/quarter with no revenue; $58.2M cash pre-offering provides ~2.6 quarters runway without the April raise

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-224214
Document: d95486d8k.htm0001193125-26-224214
Document: 0001193125-26-224214-index-headers.html0001193125-26-224214
Document: 0001193125-26-224214-index.html0001193125-26-224214
Document: 0001193125-26-224214.txt0001193125-26-224214
8-K Data (Synthetic)0001193125-26-224214

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026